Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Acceptable references to establish first/second/third line treatment
-
In a disease state that does not have authoritative Canadian consensus guidelines, could a CDA (previously CADTH) Provisional Funding Algorithm be used to support which products are recommended to be used first-line, second-line, third-line, etc. Providing this as an example: https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0047_Multiple_Myeloma.pdf.
-
Good Morning, @maryssa
Historically, as confirmed by the provided document (see Background, paragraph 2 copy “Note that provisional funding algorithms are not treatment algorithms; they are neither meant to detail the full clinical management…”), these documents are not intended to be treatment algorithms. However, Canada's Drug Agency (CDA-AMC) has an expanded mandate and role, including improving medication prescribing practices. We will reach out to CDA to discuss whether their new mandate impacts PAAB review. Stay tuned.
-
Thanks Jennifer!
In the absence of authoritative Canadian consensus guidelines, is there another reference type you can recommend to support which products are recommended to be used first-line, second-line, third-line, etc?
-
